Studies on Clinical Significance of Human Plasma Reticol-Binding Protein and Prealbumin

Analytical Studies with Cancers and Malignant Tumors

Abstract

Quantitation of the concentration of retinol-binding protein (RBP) and prealbumin in plasma and ascites from patients with cancers, malignant tumors and some diseases has been determined by the method of single radial immunodiffusion (SRID). The results showed that the levels were significantly different in those patients with cancer, malignant tumor compared with those with other benign tumors and diseases. The concentrations of plasma RBP and prealbumin in cancers and malignant tumors were shown to be significantly lower compared with those with other benign tumors, diseases and normal subjects. In addition, the plasma RBP and prealbumin are present in higher concentrations in patients with human malignant glial tumors (such as glioblastoma multiforme) and Cushing's syndrome in comparison to those concentrations with other benign brain tumors (such as meningioma), brain diseases and normal subjects. The levels of RBP and prealbumin in carcinomatous ascitic fluid (cytology-positive) were shown to be significantly higher compared with those with other carcinomatous ascitic fluid (cytology-negative). In addition, the following results were obtained in a analysis of the correlation of plasma sialic acid, C-reactive protein (CRP), 3. 5. 3.'-triiodo thyronin (T₃) and carcinoembryonic antigen (CEA) on the plasma RBP, prealbumin levels in patients with cancers and malignant tumors. In cancers and malignant tumors, the plasma levels of sialic acid, CRP, and CEA incerased by the according to decrease in levels of RBP and prealbumin, and plasma T3 levels correlate with concentrations of RBP and prealbumin.